In her most recent Industry Insights Column for eyeforpharma, NAI President, Rita Numerof, Ph.D., assesses the success of the FDA’s Breakthrough Therapy Designation, and explains what this fledgling submission process means for pharmaceutical market access.

See the full article, published November 14, 2013:  The Breakthrough Designation Program: Four Factors for Long Term Success.